OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
20
Results
Show all
Save search
Copy query
Show results for
Unknown
(20)
Publication Date
Release Date
2021
(6)
2010
(4)
2016
(3)
2023
(2)
2015
(2)
2020
(1)
2011
(1)
2008
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Exploring threats to generalisability in a large international rehabilitation trial (AVERT).
Not available
S-EPMC4550737
|
biostudies-literature
Cite
Fatal and Nonfatal Events Within 14 days After Early, Intensive Mobilization Poststroke.
Not available
S-EPMC8055346
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Not available
S-EPMC8362592
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594
|
biostudies-literature
Cite
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Not available
S-EPMC8274471
|
biostudies-literature
Cite
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
Not available
S-EPMC7953461
|
biostudies-literature
Cite
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Not available
S-EPMC7489418
|
biostudies-literature
Cite
Simvastatin in Critically Ill Patients with Covid-19.
Not available
S-EPMC10755839
|
biostudies-literature
Cite
Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.
Not available
S-EPMC10600726
|
biostudies-literature
Cite
Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT).
Not available
S-EPMC4898313
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets